MktsMarkets

Entera Bio Ltd.
NASDAQ: ENTXKey statistics
ENTX News
Stories mentioning ENTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 42.00 | 82.00 | 42.00 | 57.00 |
| Cost of Goods Sold | 0.00 | 0.00 | 0.00 | 0.00 | 42.00 | 82.00 | 42.00 | 48.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,251 | 1,718 | 1,643 | 1,520 | 1,123 | 1,201 | 1,477 | 1,086 |
| Sales General & Admin | 128.00 | 50.00 | 122.00 | 103.00 | 123.00 | 62.00 | 134.00 | |
| Total Operating Expenses | 3,539 | 3,042 | 3,256 | 2,668 | 2,563 | 2,337 | 3,021 | 2,174 |
| Operating Income (Loss) | (3,539) | (3,042) | (3,256) | (2,668) | (2,563) | (2,337) | (3,021) | (2,165) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (3,021) | |||||||
| Tax Provision | 0.00 | |||||||
| Net Income (Loss) | (3,505) | (3,016) | (3,200) | (2,656) | (2,567) | (2,358) | (3,021) | (2,145) |
| Earnings Per Share (Basic) | 0.07 | (0.07) | 0.07 | 0.06 | 0.06 | (0.06) | 0.08 | 0.06 |
| Earnings Per Share (Diluted) | 0.07 | (0.07) | 0.07 | 0.06 | 0.06 | (0.06) | 0.08 | 0.06 |
| Weighted Average Shares Outstanding (Basic) | 47,756 | 46,191 | 47,090 | 46,837 | 43,377 | 37,650 | 37,645 | 37,090 |
| Weighted Average Shares Outstanding (Diluted) | 47,756 | 46,191 | 47,090 | 46,837 | 43,377 | 37,650 | 37,645 | 37,090 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ENTX
Entera Bio Ltd. (NASDAQ: ENTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol ENTX. It last traded at $3.31 (Nov 20, 2026, 9:30 AM ET), up 0.8% on the day. That gives Entera Bio a market capitalisation of $533.9M.
Over the past 52 weeks ENTX has traded between $0.9100 and $4.20.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $3.5M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$3.5M |
| Dec 31, 2025 | $0 | -$3.0M |
| Sep 30, 2025 | $0 | -$3.2M |
| Jun 30, 2025 | $0 | -$2.7M |
From Entera Bio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…